Lexicon Pharmaceuticals IncLXRX
Price$1.88Intrinsic value$4.57143% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $41.5M+3,635.9% YoYTTM through 30 Jun 2026
Net Income -$61.1MTTM through 30 Jun 2026
Free Cash Flow -$65MTTM through 30 Jun 2026

Margins

Current
Gross Margin99.5%
EBITDA Margin-130.3%
Operating Margin-4.8%
Net Margin-147.4%

Returns

-12.9%ROE
-9.7%ROA

Balance Sheet Health

Debt / Equity0.24x
Current Ratio19.97x
Net Debt-$121Mnet cash position
Cash & Equivalents$40.9M

Quality Metrics

Altman Z-Score-3.46
Piotroski F-Score2 / 9
FCF Margin-156.7%
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $49.8M
Diluted EPS-$0.16TTM
'19'20'21'22'23'24'25
FY2025: $-0.14

Dividend

No dividend

Capital Allocation

Capex Intensity0.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.